xmlui.ArtifactBrowser.ItemViewer.show_simple

dc.contributor.authorJustino, Maria Cleonice Aguiar-
dc.contributor.authorLinhares, Alexandre da Costa-
dc.contributor.authorLanzieri, Tatiana M-
dc.contributor.authorMiranda, Yllen-
dc.contributor.authorMascarenhas, Joana D'Arc Pereira-
dc.contributor.authorAbreu, Erika-
dc.contributor.authorGuerra, Sylvia de Fátima dos Santos-
dc.contributor.authorOliveira, Alessilva do Socorro Lima de-
dc.contributor.authorSilva, Veronilce B da-
dc.contributor.authorSanchez, Nervo-
dc.contributor.authorMeyer, Nadia-
dc.contributor.authorShafi, Fakrudeen-
dc.contributor.authorOrtega-Barria, Eduardo-
dc.contributor.authorSoriano-Gabarró, Montse-
dc.contributor.authorColindres, Romulo E-
dc.date.accessioned2018-07-19T11:40:52Z-
dc.date.available2018-07-19T11:40:52Z-
dc.date.issued2011-
dc.identifier.citationJUSTINO, Maria Cleonice Aguiar et al. Effectiveness of the monovalent G1P[8] rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil. Pediatric Infectious Disease Journal, v. 30, n. 5 ,p. 396 - 401, May 2011.pt_BR
dc.identifier.issn0891-3668-
dc.identifier.urihttp://patua.iec.gov.br//handle/iec/3264-
dc.description.abstractBackground: Brazil initiated universal immunization of infants with the G1P_8_ human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control study conducted at 4 hospitals in Belém from May 2008 to May 2009. Cases were children hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (_12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (_8 and _6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 _ odds ratio _ 100 percent). Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54 percent, 61 percent, and 74 percent had received both RV vaccine doses. VE against RVGE hospitalization was 75.8 percent (95 percent confidence interval _CI_: 58.1û 86.0) using neighborhood controls and 40.0 per cent (95 per cent CI: 14.2û58.1) using hospital controls. VE in children 3 to 11 months and _12 months of age was 95.7per cent (95 per cent CI: 67.8 û99.4) and 65.1 per cent (95 per cent CI: 37.2û 80.6) using neighborhood controls, and 55.6 per cent (95 per cent CI: 12.3û77.5) and 32.1 per cent (95 per cent CI: _3.7û55.5) using hospital controls. G2P_4_ accounted for 82.0 per cent of RVGE hospitalizations. G2P 4 -specific VE was 75.4 per cent (95 per cent CI: 56.7û 86.0) using neighborhood controls and 38.9 per cent (95 per cent CI: 11.1û 58.0) using hospital controls. Conclusions: Although fully heterotypic G2P 4 was the predominant RV strain, good VE was demonstrated. VE was highest in children aged 3 to 11 for 82.0 per cent of RVGE hospitalizations. G2P_4_-specific VE was 75.4 per cent (95 per cent CI: 56.7û 86.0) using neighborhood controls and 38.9 per cent (95 per cent CI: 11.1û 58.0) using hospital controls.pt_BR
dc.description.sponsorshipSupported by the GlaxoSmithKline Biologicals.pt_BR
dc.language.isoengpt_BR
dc.publisherLippincott, Williams & Wilkinspt_BR
dc.rightsAcesso Abertopt_BR
dc.titleEffectiveness of the monovalent G1P[8] rotavirus vaccine against hospitalization for severe G2P[4] rotavirus gastroenteritis in Belém, Brazil.pt_BR
dc.typeArtigopt_BR
dc.subject.decsPrimaryGastroenterite / virologiapt_BR
dc.subject.decsPrimaryRotavirus / isolamento & purificaçãopt_BR
dc.subject.decsPrimaryVacinas contra Rotaviruspt_BR
dc.subject.decsPrimaryHospitalizaçãopt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationGlaxoSmithKline. Rio de Janeiro, RJ, Brazil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationMinistério da Saúde. Secretaria de Vigilância em Saúde. Instituto Evandro Chagas. Belém, PA, Brasil.pt_BR
dc.creator.affilliationGlaxoSmithKline. Rio de Janeiro, RJ, Brazil.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals. Wavre, Belgium.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals. Bangalore, India.pt_BR
dc.creator.affilliationGlaxoSmithKline. Rio de Janeiro, RJ, Brazil.pt_BR
dc.creator.affilliationGlaxoSmithKline Biologicals. Wavre, Belgium.pt_BR
dc.creator.affilliationGlaxoSmithKline. Rio de Janeiro, RJ, Brazil.pt_BR
dc.identifier.doi10.1097/INF.0b013e3182055cc2-


xmlui.dri2xhtml.METS-1.0.item-files-head

Thumbnail

xmlui.ArtifactBrowser.ItemViewer.head_parent_collections

xmlui.ArtifactBrowser.ItemViewer.show_simple